Aptar acquires two leading pharma analytical service companies

10 Jun 2019

Will support pharmaceutical and biotech customers to accelerate and derisk their complex product developments.

AptarGroup has acquired two leading pharma analytical services companies, Nanopharm and Gateway Analytical, for a combined enterprise value of approximately $50 million. The acquisitions are part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments.

Aptar acquires two leading pharma analytical service companies

Both acquisitions bring complementary, value-added and differentiated analytical, testing and development services for all stages of drug development and commercialization. The expanded services platform will enable Aptar Pharma to collaborate earlier with customers to support their complex drug formulations and delivery requirements as they face increasingly competitive and regulated markets.

Nanopharm: broadening Aptar Pharma’s services offering in Inhalation

A specialist in respiratory drug delivery services, Nanopharm is a science-driven, leading provider of orally inhaled and nasal drug product (OINDP) design and development services to customers worldwide.

Nanopharm’s specialized contract research services complements Aptar Pharma’s existing broad range of analytical and product development services, and are directly aligned to Aptar Pharma’s device portfolio in Nasal and Inhaled products. Nanopharm’s goal is to enable and accelerate OINDPs’ seamless translation of preclinical development through to clinical manufacture.

Located in Newport, UK, Nanopharm employs 37 people at their state-of-the art analytical facility.

“We are pleased to welcome Nanopharm, their team of experts and their customers to Aptar Pharma and our Services business,” comments Gael Touya, President of Aptar Pharma. “This acquisition, which deepens our current range of services in Inhalation, will enable us to provide additional cutting-edge science-based services focused on further understanding and developing inhalation and nasal formulations.”

Nanopharm Founder and Chief Scientific Officer Prof. Robert Price said “In Aptar we have found the ideal partner to continue the successful growth of Nanopharm. Aptar Group is perfectly positioned to support the development of our science-driven, solution-oriented services for inhalation and nasal drug products. This exciting new chapter in our development will allow us to deliver yet more as we leverage Aptar’s expertise and infrastructure to better serve our highly-valued clients.”

CEO Dr Jag Shur added “Our decision to join forces with Aptar Group has been made very carefully indeed. This synergistic partnership and shared commitment to scientific excellence will enable us to better serve our clients by offering a broader spectrum of innovative solutions and enhance our level of technical services going forward. The future of Nanopharm as part of the Aptar Group is very exciting indeed.”

Both Prof. Price and Dr Shur will continue in their roles at Nanopharm post-acquisition.

Gateway Analytical: broadening Aptar Pharma’s services offering for Injectables

Gateway Analytical provides industry-leading pharmaceutical, medical device, materials, predictive maintenance and forensics analysis services to customers worldwide.

Gateway is a recognized expert in particle detection and analysis. The appearance of particles is a real concern in the pharmaceutical industry, and in injectable drugs in particular. Particle-related issues have led to a significant number of product recalls for injectable products over the years, so their detection and identification is of great importance to pharmaceutical laboratories. Gateway’s unrivaled expertise, leading database and state-ofthe-art equipment in this field enhance the flexibility and speed with which its pharmaceutical customers can bring and maintain their products on the market.

Founded in 2011, Gateway Analytical, located in Gibsonia, PA, employs 18 analytical experts at its cGMP compliant, FDA inspected, ISO 9001 and 17025 accredited 17,000-sq ft facility.

Gateway’s specialized analytical services complement Aptar Pharma’s existing broad range of analytical and testing services designed to proactively address regulatory needs to accelerate approval, launch and support post-marketing surveillance in the competitive pharmaceutical space. Gateway’s rigorous and customer-centric approach can help ensure that not only are regulatory guidelines met, but unnecessary and costly product withdrawals and potential harm to patients from particles avoided.

“We are also pleased to add Gateway Analytical, their team of experts and their customers to Aptar Pharma and our Services business,” comments Gael Touya, President of Aptar Pharma. “This additional acquisition further broadens our expertise and plays a vital role in our strategy of continuing to provide reliable, high quality, specialized analytical testing services to our customers, especially in Injectables.”

“We are delighted to join Aptar Pharma, a leader in the field of drug delivery devices and value-added services to their pharmaceutical customers,” adds David Exline, President of Gateway Analytical. “With our combined resources and teams we can offer customers a broader range of specialized and differentiated products and services, and maintain the superior level of service and quality they’ve been receiving from Gateway Analytical. In addition, our worldwide reach will be significantly enhanced with the leadership of Aptar Pharma.”

Nanopharm and Gateway will continue to operate as separate entities. They join Next Breath, a full-service cGMP compliant laboratory specializing in analytical testing which was acquired by Aptar Pharma in 2008, as part of Aptar Pharma Services.

Stephan Tanda, President and CEO, stated: “These strategic investments further strengthen our best in class Pharma business and increase our ability to add to our long-term growth pipeline by adding depth to our service offerings. The expertise of two established leaders, Nanopharm, a leader in inhalation and nasal drug development services, and Gateway, a leader in particulate detection and analysis for the injectables market, are complementary to our existing laboratory and analytical services and will bring additional value to our customers as they navigate the challenging regulatory landscape and seek to bring their products to market faster.”

Read More